-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment

PUBT·10/08/2026 11:32:39
Listen to the news
Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment
  • Clearmind Medicine published a Japanese patent application covering 3-MMC-based methods and compositions to prevent or treat dyskinesia.
  • Claims also cover combining 3-MMC with palmitoylethanolamide, targeting an added anti-inflammatory or neuroprotective effect.
  • The filing expands the company’s intellectual property footprint for its 3-MMC program in neurological movement disorders.
  • Work ties to Clearmind’s collaboration with NeuroThera Labs, which contributes palmitoylethanolamide technology to its therapeutic platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080732PRIMZONEFULLFEED9842147) on October 08, 2026, and is solely responsible for the information contained therein.